Proteasome inhibitors are emerging as effective drugs for the treatment of multiple myeloma and possibly certain subtypes of non-Hodgkin's lymphoma. Bortezomib (Velcade) is the first proteasome inhibitor proven to be clinically useful and will soon be followed by a second generation of small molecule inhibitors with improved pharmacological properties. Although it is now understood that certain types of malignancies have an exquisite dependence on a functional proteasome for their survival, the underlying reason(s) remain unclear as of now. In this context, addiction to nuclear factor-jB (NF-jB)-induced survival signals, activation of the unfolded protein response as well as a reduced proteasomal activity in differentiated plasma cells have all been proposed to justify proteasome inhibitors' activity in susceptible tissues. In addition to their anticancer properties, bortezomib and related drugs modulate inflammatory and immune responses by affecting function and survival of immune cells such as lymphocytes and dendritic cells. The present review offers an overview of the biological effects that have been involved in proteasome inhibitors' antitumor activity and suggests prospective future applications for these drugs based on their recently characterized anti-inflammatory and immunomodulatory effects. The ubiquitin-proteasome pathway and its relevance to cancer
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The ubiquitin-proteasome pathway (UPP) mediates the degradation of polyubiquitinated proteins and represents the main protein degradation pathway in eucaryotic cells. 1 It is estimated that more than 80% of intracellular proteins are degraded by the proteasome. Besides carrying out protein turnover, the UPP plays an essential role in regulating protein levels during cell cycle, apoptosis, response to cellular stress (i.e. DNA damage, hypoxia) and intracellular signal transduction, not to mention its importance for the generation of antigenic epitopes to be presented on human leukocyte antigen (HLA) molecules. It is now known that some types of cancer are exquisitely prone to undergo apoptosis in response to inhibition of the UPP pathway, a phenomenon that, at present, still lacks a precise explanation. 2, 3 Intracellular proteins are targeted for degradation by the conjugation of polyubiquitin chains to lysine residues of the protein, a process carried out by ubiquitin-conjugating enzymes and antagonized by deubiquitinating proteases (revised by Nijman et al. 4 ). 1 Ubiquitination is performed by three enzymes: a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin ligase (E3). E1 activates ubiquitin monomers by adenylation and transfers them to E2, which in turn works in conjunction with E3 to confer substrate specificity. Whereas E1 only exists in two isoforms derived from alternative splicing of the same messenger at least 25 E2 and hundreds of E3 enzymes exist. 1 A similar complexity is shared by the deubiquitinating enzymes, of which more than 500 are represented in the human genome, thus indicating the high complexity and specificity of this regulatory mechanism. 4 The proteasome is an enzymatic complex that recognizes ubiquitin-tagged proteins and catalyses their proteolytic degradation in an ATP-dependent fashion. [1] [2] [3] Proteasomes can be found both in the cytoplasm and in the nucleus of eucaryotic cells. The proteasome typically consists of a 20S component, which is normally associated to a 19S or to an 11S (inducible by interferon-g) regulator component. The 20S proteasome component is comprised of a-and b-subunits. b1, b2 and b5 are the polypeptides that perform the proteasome enzymatic activities, these consisting of chymotryptic-like (b5), tryptic-like (b2) and caspase-like (b1) activities. Most proteasome inhibitors including bortezomib are believed to work by inhibiting the chymotryptic-like activity of the 20S proteasome (b5-subunit), even though recent evidence indicates that the b1-and b2-subunits may also be inhibited by bortezomib, especially when high drug concentrations are used (Driessen C et al. Whereas proteasome-mediated protein turnover appears to be ubiquitous in both immune and non-immune cells, it has to be observed that regulation via ubiquitination is essential to many proteins involved in tumorigenesis, such as the cyclins, cyclindependent kinases, cyclin-dependent kinase inhibitors, cdc25 phosphatase, nuclear factor kB (NF-kB), C-fos, C-jun, N-MYC, p53, Bax, b-catenin, SNAIL and hypoxia-inducible factor 1alpha (HIF1-a). [1] [2] [3] 6, 7 In addition, many oncogenes and tumor suppressors are themselves involved in ubiquitination (usually as E3 ligases) or are deubiquitinating enzymes. 1, 4, 8 Examples of E3 ligases that have been linked to cancer include MDM2, which regulates p53 and is overexpressed in many cancers, particularly sarcomas; 1, 8 BRCA1, a tumor suppressor involved in breast and ovarian cancer susceptibility; Von Hippel-Lindau (VHL), whose mutation is detected in most kidney cancers and determines HIF1-a stabilization and angiogenesis induction; E6-AP, another p53 regulator activated by the human papilloma virus oncogene E6; and SKP2, an oncogene that, upon overexpression, leads to UPP-mediated removal of cell cycle regulators such as p27, p21 and p57. Among the deubiquitinating enzymes related to cancer, it is important to note the recent functional annotation of the tumor suppressor CYLD (mutated in familial cylindromatosis) whose deletion was shown to lead to constitutive NF-kB activation. [9] [10] [11] This bulk of evidence clearly indicates the importance of UPP function in cancer and has lead to different hypothesis regarding why UPP blockade would be 'more' toxic to cancer vs normal cells. Some of the effects of proteasome inhibition on these regulatory pathways will be further discussed in this review. However, it should be premised that none of these mechanisms has reached a sufficient level of evidence to fully explain the cytotoxic effects of proteasome inhibitors in general or in specific types of cancer, thus leaving a significant knowledge gap that numerous research efforts are presently trying to fill.
Mechanisms of anticancer activity of proteasome inhibitors
As mentioned above, several mechanisms have been proposed to explain the antitumor activity of proteasome inhibitors, and they mostly result from impeded degradation of proapoptotic and/or regulatory proteins:
NF-kB inhibition through reduced IkBa degradation, leading to reduced NF-kB-dependent synthesis of antiapoptotic factors, such as c-Flip, inhibitor of apoptosis (IAP)1/2, and Bcl-2, and of angiogenic factors; 2, 3 stabilization and accumulation of p53; 2, 3 deregulation of cyclins turnover and subsequently of cyclindependent kinases activity; 2, 3 effect on stability of cdc25 family proteins, KIP1 and WAF1 during cell cycle; 2, 3 shift in the balance between pro-and antiapoptotic Bcl-2-family proteins; 2, 3 JNK stabilization, increased c-Jun phosphorylation and AP-1 DNA-binding activity with subsequent Fas upregulation; 12 deregulated proapoptotic signaling via tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); 13, 14 disruption of the unfolded protein response with endoplasmic reticulum (ER) stress induction; 15 increased intracellular reactive oxygen species and oxidative stress; 16 reversal of interleukin (IL)-6-and insulin growth factor (IGF)-1-mediated antiapoptotic effects; 5 reduced multiple myeloma cells, migratory capacity in response to VEGF; 17 and effect of proteasome inhibitors on the tumor microenvironment, including antiangiogenic effects. 18 Of particular interest is the recent observation that terminally differentiated immunoglobulin (Ig)-secreting plasma cells would have impaired proteasome activity. 19 The reduced proteolytic capacity is accompanied by accumulation of polyubiquitinated proteins, stabilization of substrates such as Ik-Ba and Bax, apoptosis induction and sensitization to proteasome inhibitors. This effect has been suggested to help control plasma cell lifespan and Ig production. Additionally, it would nicely explain the exquisite sensitivity of malignant plasma cells to bortezomib and related drugs. Further investigation in this direction is obviously warranted, including an evaluation of baseline proteasomal activity in cancers that show susceptibility vs resistance to proteasome inhibitors.
Whichever the initial trigger for cell demise is, proteasome inhibition was shown in different experimental models to initiate an apoptotic cascade mediated by caspases. 2, 5, 12, 13, [20] [21] [22] [23] The respective contribution of the intrinsic mitochondrial apoptotic pathway (via caspase-9) vs the death receptor pathway (via caspase-8) vs ER stress (via caspase-12) to this process is still debated and may depend on the experimental or clinical setting, or even on the type of proteasome inhibitor used, as suggested by a direct comparison between bortezomib and NPI-0052. 5 In vitro co-treatment with proteasome inhibitors removes resistance and increases sensitivity to different types of anticancer drugs, including traditional antiblastics and g-irradiation,
2,3 as well as more novel therapeutics such as rituximab, histone deacetylase inhibitors, farnesyl transferase inhibitors, tyrosine kinase inhibitors and the cyclin-dependent kinase inhibitor flavopiridol (Bisping G et al. Blood 2005; 106: 112; abstract). [24] [25] [26] [27] [28] In this context, we have demonstrated that proteasome inhibitors synergistically interact with recombinant TRAIL to overcome chemoresistance and induce apoptosis in chemoresistant Bcl-2-overexpressing lymphoma cells. 23 Interestingly, the cytotoxic effects of proteasome inhibitors have repeatedly been observed to depend on active protein synthesis within the cell, as the translation inhibitor cycloheximide typically blocks proteasome inhibitor-induced apoptosis at a very upstream stage. 22, 29, 30 Whether this is due to an interference by cycloheximide with the general mechanism of intracellular proteins accumulation via proteasome inhibition, or rather is due to an effect of cycloheximide on specific proapoptotic factors that would otherwise be synthesized, is presently still unclear. Finally, it has to be noted that proteasome inhibitors paradoxically also trigger accumulation or even de novo synthesis of antiapoptotic factors with the capacity to reduce the cytotoxic effect of the drug. For instance, bortezomib treatment typically induces upregulation of heat-shock protein 90 (HSP90), a chaperone protein known to support the function of client proteins (including IL-6 and IGF-R1) in multiple myeloma.
31,32 Additionally, we have recently shown that proteasome inhibitors, including bortezomib, lead to intracellular accumulation of the antiapoptotic Bcl-2 family member Mcl-1, which holds back the apoptotic response to the proteasome inhibitor itself. 20, 33 These counterproductive effects create room for therapeutic intervention with pharmacological and/or genetic inhibitors of the unwanted proteins. In this context, the HSP90 inhibitor KOS-953 was first shown to enhance bortezomib activity in myeloma cells in vitro and its safety and efficacy in combination with bortezomib are presently explored in clinical studies (Chanan-Khan AA et al. Blood 2005; 106: 362; abstract).
Clinical experience with bortezomib in cancer
The proteasome inhibitor bortezomib has been evaluated in a number of published and ongoing trials for solid and hematological malignancies. Bortezomib is presently approved by the Food and Drug Administration for use in multiple myeloma patients who have received at least one prior therapy. Moreover, the Food and Drug Administration has recently granted this proteasome inhibitor fast track status for relapsed and refractory mantle cell lymphoma. Bortezomib's activity in other forms of cancer remains uncertain, possibly with the only exception of non-small-cell lung cancer, where single-agent bortezomib appears to have similar activity to single-agent docetaxel, pemetrexed and erlotinib. 34 Tables 1-3 present a synopsis of the trials with bortezomib for multiple myeloma and lymphomas, including some of the ongoing studies that were presented at the 2005 Meeting of the American Society of Hematology. 
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Proteasome inhibitors in graft-versus-host disease and immune disorders
Proteasome inhibitors affect several aspects of immune and inflammatory responses by interfering with antigen processing, apoptosis, cell cycle, co-stimulation, adhesion and chemotaxis. 48 Their capacity to prevent NF-kB activation has made them particularly appealing candidates for the treatment of immune-mediated disorders, considering the importance of this transcription factor in inflammation. Accordingly, several preclinical studies were undertaken that demonstrated the efficacy of proteasome inhibitors in the treatment of arthritis, psoriasis, experimental autoimmune encephalomyelitis and allograft rejection. [49] [50] [51] [52] Of particular interest is the application of proteasome inhibitors in preventing the deleterious effects of graft-versus-host disease (GVHD), a potentially lethal immune aggression of the recipient mediated by immune cells from the donor following allogeneic bone marrow (or peripheral blood precursor cells) transplantation. Bortezomib efficiently prevents acute GVHD in the mouse while apparently not affecting the beneficial graft-versus-tumor effects. [53] [54] [55] Sun et al. 53 went on to show that this result might be achieved only when bortezomib administration immediately follows bone marrow transplantation. Conversely, delayed administration (3 or more days after transplant) appears to increase GVHD-dependent gastrointestinal toxicity. 54, 55 The latter effect was associated with TNF-areceptor upregulation in gastrointestinal cells and with significant increases of TNF-a, IL-1b and IL-6 serum levels. GVHD inhibition through bortezomib has been proposed to be due to selective apoptosis and decreased Th1 response among alloreactive T-lymphocytes, although whether these effects are mediated by NF-kB inhibition in activated T cells is uncertain. 56 For instance, the specific NF-kB inhibitor PS-1145 prevented GVHD similarly to bortezomib, but failed to exacerbate this reaction when given later after transplant, suggesting that different regulatory mechanisms are touched by the two drugs. A central role in immunity and immune-mediated disorders is played by dendritic cells (DCs), specialized antigen-presenting cells that stimulate the expansion of antigen-specific T-lymphocytes and determine the features of an immune response. 57 Deregulated DC function and survival have been proposed to predispose to autoimmunity. 58, 59 We have recently reported that proteasome inhibitors exert multiple effects on human DCs, including modulation of DC immunostimulatory capacity, downregulation of co-stimulation molecules and cytokines, reduced migration and antigen-uptake capacity and increased predisposition to apoptosis. 30, 60 We found that bortezomib was particularly effective in preventing DCs activation in response to lipopolysaccharide and to endogenous inflammatory signals, where this inhibition could be attributed to interference with NF-kB, the MAP kinase pathway and interferon response factor (IRF)-3 and IRF-8. Bortezomib's effects on DCs may explain, at least partially, the beneficial effects observed with this drug in the preclinical models of immune-mediated disorders. However, whether proteasome inhibitors interfere with antigenpresenting cell activity and survival in vivo in humans has to be determined yet.
Finally, proteasome inhibition interferes with the processing of endogenous proteins for presentation on HLA molecules and this effect was shown to favour the presentation of exogenously added peptide epitopes by DCs. 61, 62 Thus, DC treatment with proteasome inhibitors has been proposed to improve DC-based vaccinations. However, the detrimental effects of proteasome inhibition on DC immunogenicity should also be taken into account in this setting, as these may result in the induction of anergy instead of effective immunization.
Proteasome inhibitors in the treatment of ischemic stroke and cardiovascular disease Cardiovascular diseases and ischemic stroke are major causes of morbidity and mortality in developed countries. Interestingly, accumulating evidence points to potential beneficial effects of proteasome inhibitors administration in these settings, in that they prevented ischemia-reperfusion injury in the brain, heart and kidney in animal models. [63] [64] [65] Although the mechanism through which proteasome inhibition confers protection is still debated, NF-kB inactivation appears to be important as it downregulates cytokine secretion and cell adhesion molecules during the reperfusion phase. [63] [64] [65] On the other hand, the role of the proteasome in ischemia appears to be multifaceted and major concerns regarding the use of inhibitors in ischemic disorders still remain. In fact, it is believed that the UPP also carries out the processing and removal of degraded and misfolded proteins after tissue damage and, in general, its function is important for cellular growth, metabolism and repair. Finally, bortezomib has potential neurotoxic effects in humans and its use in patients with ischemic stroke should thus be carefully considered.
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Concluding remarks
In an era of discovery and experimentation of molecular targeting therapeutics that selectively target oncogenes and tumor-associated antigens, the emergence of proteasome inhibitors as one of the most promising drug classes is somehow surprising and unexpected, especially given the assumed extreme lack of specificity of these compounds. This demonstrates that our knowledge of the properties of tumor cells is still far from complete and that, beside drug intelligent design, cancer's Achilles' heel should still be actively searched through unbiased approaches, including the traditional compound screens and the more recent chemical-genetic interaction screens searching for synthetic lethal interactions in specific cancer genotypes. 66 Now that bortezomib and related drugs have been shown to be effective, more research is required to explain the mechanism of activity of these compounds. Whether proteasome inhibitors will also be useful for the treatment of inflammatory/immunological diseases needs to be further evaluated.
